Medpace Holdings, Inc. $MEDP Stock: Aberdeen Group plc Grows Holdings

Aberdeen Group plc boosted its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 5,119.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,231,252 shares of the company’s stock after buying an additional 2,188,504 shares during the quarter. Medpace makes up approximately 1.5% of Aberdeen Group plc’s portfolio, making the stock its 12th largest holding. Aberdeen Group plc owned approximately 0.08% of Medpace worth $1,392,703,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Johnson Financial Group Inc. purchased a new stake in Medpace during the 2nd quarter worth approximately $27,000. Jones Financial Companies Lllp purchased a new position in shares of Medpace in the second quarter valued at approximately $30,000. Allied Private Wealth LLC purchased a new position in shares of Medpace in the second quarter valued at approximately $31,000. Kilter Group LLC acquired a new stake in shares of Medpace in the second quarter worth approximately $31,000. Finally, Basecamp Wealth Advisors LLC boosted its stake in shares of Medpace by 187.5% in the first quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock worth $33,000 after acquiring an additional 45 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently commented on MEDP. Robert W. Baird set a $699.00 price target on Medpace in a research report on Friday, October 23rd. UBS Group raised their price objective on Medpace from $673.00 to $700.00 and gave the company a “neutral” rating in a report on Friday, October 23rd. Barclays lifted their target price on shares of Medpace from $625.00 to $675.00 and gave the stock an “equal weight” rating in a research note on Friday, October 23rd. Weiss Ratings raised shares of Medpace from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, October 8th. Finally, Mizuho set a $730.00 target price on shares of Medpace in a report on Friday, October 23rd. Three analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $649.27.

Insider Activity

In related news, VP Susan Burwig sold 3,940 shares of the company’s stock in a transaction that occurred on Tuesday, October 27th. The stock was sold at an average price of $677.00, for a total value of $2,667,380.00. Following the transaction, the vice president directly owned 54,012 shares in the company, valued at approximately $36,566,124. This represents a 6.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO August Troendle sold 21,966 shares of the stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $625.47, for a total value of $13,739,074.02. Following the completion of the transaction, the chief executive officer owned 338,225 shares of the company’s stock, valued at $211,549,590.75. The trade was a 6.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 306,539 shares of company stock valued at $191,774,429. 20.50% of the stock is currently owned by company insiders.

Medpace Trading Down 0.4%

Shares of MEDP stock opened at $653.94 on Friday. The company’s 50-day moving average price is $629.52 and its 200-day moving average price is $533.79. The stock has a market cap of $18.29 billion, a price-to-earnings ratio of 36.41, a PEG ratio of 2.55 and a beta of 1.12. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $693.97.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, October 21st. The company reported $4.84 EPS for the quarter, topping analysts’ consensus estimates of $4.44 by $0.40. Medpace had a net margin of 18.24% and a return on equity of 99.76%. The company had revenue of $716.00 million for the quarter, compared to the consensus estimate of $714.47 million. Medpace’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.86 earnings per share. As a group, equities research analysts predict that Medpace Holdings, Inc. will post 18.06 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc. is a global contract research organization (CRO) that provides clinical development services to the biotechnology, pharmaceutical and medical device industries. Founded in 1992 and headquartered in Cincinnati, Ohio, the company works with clients developing treatments and medical products across a range of therapeutic areas. Medpace offers services spanning the clinical development process, including clinical trial planning and management, regulatory affairs, clinical laboratory testing, data management, biostatistics, medical writing and pharmacovigilance.